Drug information provided by: Merative, Micromedex®
Rituximab and hyaluronidase human, recombinant combination injection is used alone or together with other cancer medicines to treat follicular lymphoma and chronic lymphocytic leukemia (CLL). It is also used together with other medicines to treat diffuse large B-cell lymphoma (DLBCL) in people who have not received previous treatment.
Rituximab and hyaluronidase human, recombinant combination injection is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Aug. 01, 2023
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Join our Year-End Challenge and triple your gift to help shape the future of healthcare!